These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.
    Author: van Riel PL, van Gestel AM, van de Putte LB.
    Journal: Br J Rheumatol; 1995 Nov; 34 Suppl 2():40-2. PubMed ID: 8535648.
    Abstract:
    In a cohort of patients with early rheumatoid arthritis, sulphasalazine (SASP) was mainly given as a first-choice second-line agent. SASP resulted in a significantly better survival rate compared with hydroxychloroquine, which is also given as a first-choice agent. When the survival rate of SASP was compared with that of aurothioglucose, both given as second-choice agents, again, a statistically significant better survival rate was found for SASP. In 9% of the patients, SASP could be withdrawn as a complete remission was obtained. Adverse reactions occurred mainly during the first 3 months of treatment, and in 20% of patients these were severe enough to stop treatment. Gastrointestinal adverse reactions were most frequently observed, and all adverse reactions were completely reversible after treatment withdrawal. Treatment was started with a standard dose of 2000 mg/day. However, in approximately 30% of the patients, this dose was increased up to 3000 mg/day and, in another 30%, the dose was decreased to 1,500 or 1,000 mg/day.
    [Abstract] [Full Text] [Related] [New Search]